WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 581198
Description: Dacopafant is platlet activationg factor receptor (PAFR) antagonists. It had been in phase I clinical trials by Sanofi for the treatment of systemic inflammatory response syndrome and asthma. However, this research has been discontinued.
MedKoo Cat#: 581198
Chemical Formula: C12H11N3OS
Exact Mass: 245.0623
Molecular Weight: 245.3
Elemental Analysis: C, 58.76; H, 4.52; N, 17.13; O, 6.52; S, 13.07
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Dacopafant; UNII-H1T03Z1G60;
IUPAC/Chemical Name: (3R)-3-(3-Pyridyl)-1H,3H-pyrrolo(1,2-c)thiazole-7-carboxamide
InChi Key: ARFOASMERCHFBY-GFCCVEGCSA-N
InChi Code: InChI=1S/C12H11N3OS/c13-11(16)9-3-5-15-10(9)7-17-12(15)8-2-1-4-14-6-8/h1-6,12H,7H2,(H2,13,16)/t12-/m1/s1
SMILES Code: O=C(C(C=C1)=C2N1[C@@H](C3=CC=CN=C3)SC2)N
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 245.3 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Serradji N, Bensaid O, Martin M, Kan E, Dereuddre-Bosquet N, Redeuilh C, Huet J, Heymans F, Lamouri A, Clayette P, Dong CZ, Dormont D, Godfroid JJ. Structure-activity relationships in platelet-activating factor (PAF). 10. From PAF antagonism to inhibition of HIV-1 replication. J Med Chem. 2000 Jun 1;43(11):2149-54. PubMed PMID: 10841793.
2: Clayette P, Dereuddre-Bosquet N, Martin M, Fretier P, Dormont D. Effects of RP 55778, a tumor necrosis factor alpha synthesis inhibitor, on antiviral activity of dideoxynucleosides. Antimicrob Agents Chemother. 1997 Apr;41(4):875-7. PubMed PMID: 9087512; PubMed Central PMCID: PMC163817.
3: Renesto P, Vicart P, Paulin D, Chignard M. Protective effect of platelet activating factor antagonists on cultured endothelial cell lysis induced by elastase or activated neutrophils. Br J Pharmacol. 1996 Mar;117(5):902-6. PubMed PMID: 8851508; PubMed Central PMCID: PMC1909414.
4: van Rossem K, Vermariën H, Decuyper K, Bourgain R. The role of PAF and the effect of a specific PAF antagonist on local tissue PO2 and neuronal integrity during and after photothrombotic brain infarction in unanesthetised rabbits. Adv Exp Med Biol. 1996;388:423-9. PubMed PMID: 8798843.
5: Koike H, Imanishi N, Natsume Y, Morooka S. Effects of platelet activating factor receptor antagonists on intracellular platelet activating factor function in neutrophils. Eur J Pharmacol. 1994 Nov 15;269(3):299-309. PubMed PMID: 7895770.